These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28515807)

  • 1. External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer.
    Tiberi D; Rodrigues G; Pickles T; Morris J; Crook J; Martin AG; Cury F; Catton C; Lukka H; Warner A; Taussky D
    Can Urol Assoc J; 2017; 11(3-4):94-100. PubMed ID: 28515807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of ProCaRS Clinical Nomograms for Biochemical Failure-free Survival Following Either Low-Dose Rate Brachytherapy or Conventionally Fractionated External Beam Radiation Therapy for Localized Prostate Cancer.
    Warner A; Pickles T; Crook J; Martin AG; Souhami L; Catton C; Lukka H; Rodrigues G
    Cureus; 2015 Jun; 7(6):e276. PubMed ID: 26180700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prostate cancer risk stratification (ProCaRS) project: recursive partitioning risk stratification analysis.
    Rodrigues G; Lukka H; Warde P; Brundage M; Souhami L; Crook J; Cury F; Catton C; Mok G; Martin AG; Vigneault E; Morris J; Warner A; Gonzalez Maldonado S; Pickles T;
    Radiother Oncol; 2013 Nov; 109(2):204-10. PubMed ID: 24231239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prostate cancer risk stratification project: database construction and risk stratification outcome analysis.
    Rodrigues G; Lukka H; Warde P; Brundage M; Souhami L; Crook J; Cury F; Catton C; Mok G; Martin AG; Vigneault E; Morris J; Warner A; Maldonado SG; Pickles T;
    J Natl Compr Canc Netw; 2014 Jan; 12(1):60-9. PubMed ID: 24453293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
    Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data.
    Loblaw A; Pickles T; Crook J; Martin AG; Vigneault E; Souhami L; Cury F; Morris J; Catton C; Lukka H; Cheung P; Sethukavalan P; Warner A; Yang Y; Rodrigues G;
    Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):161-170. PubMed ID: 27780694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study.
    Zelic R; Garmo H; Zugna D; Stattin P; Richiardi L; Akre O; Pettersson A
    Eur Urol; 2020 Feb; 77(2):180-188. PubMed ID: 31606332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) dose escalation or low-dose rate (LDR) brachytherapy.
    Krishnan V; Delouya G; Bahary JP; Larrivée S; Taussky D
    BJU Int; 2014 Dec; 114(6):865-71. PubMed ID: 24274784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy.
    Peng LC; Narang AK; Gergis C; Radwan NA; Han P; Marciscano AE; Robertson SP; He P; Trieu J; Ram AN; McNutt TR; Griffith E; DeWeese TA; Honig S; Singh H; Greco SC; Tran PT; Deville C; DeWeese TL; Song DY
    Urol Oncol; 2018 Jun; 36(6):309.e7-309.e14. PubMed ID: 29551548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CAPRA score versus sub-types of minimal residual disease to predict biochemical failure after external beam radiotherapy.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
    Ecancermedicalscience; 2020; 14():1042. PubMed ID: 32565895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy.
    Punnen S; Freedland SJ; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Carroll PR; Cooperberg MR
    Eur Urol; 2014 Jun; 65(6):1171-7. PubMed ID: 23587869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of three risk assessment tools in Australian patients with prostate cancer.
    Tamblyn DJ; Chopra S; Yu C; Kattan MW; Pinnock C; Kopsaftis T
    BJU Int; 2011 Nov; 108 Suppl 2():51-6. PubMed ID: 22085129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer.
    King MT; Yang DD; Muralidhar V; Mahal B; Butler S; Devlin PM; Lee LJ; Mouw KW; Martin NM; D'Amico AV; Nguyen PL; Orio PF
    Brachytherapy; 2019; 18(2):186-191. PubMed ID: 30638912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limitations of the Cancer of the Prostate Risk Assessment (CAPRA) Prognostic Tool for Prediction of Metastases and Prostate Cancer-specific Mortality in Patients Treated With External Beam Radiation Therapy.
    Vainshtein JM; Schipper M; Vance S; Feng FY; Olson KB; Hamstra DA
    Am J Clin Oncol; 2016 Apr; 39(2):173-80. PubMed ID: 24487421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High biologically effective dose radiation therapy using brachytherapy in combination with external beam radiotherapy for high-risk prostate cancer.
    Okamoto K; Wada A; Kohno N
    J Contemp Brachytherapy; 2017 Feb; 9(1):1-6. PubMed ID: 28344597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes following iodine-125 prostate brachytherapy with or without neoadjuvant androgen deprivation.
    Ohashi T; Yorozu A; Saito S; Momma T; Toya K; Nishiyama T; Yamashita S; Shiraishi Y; Shigematsu N
    Radiother Oncol; 2013 Nov; 109(2):241-5. PubMed ID: 24183866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation and comparison of the two Kattan nomograms in patients with prostate cancer treated with (125) iodine brachytherapy.
    Kaplan A; German L; Chen J; Matzkin H; Mabjeesh NJ
    BJU Int; 2012 Jun; 109(11):1661-5. PubMed ID: 22115188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer.
    Murray NP; Aedo S; Fuentealba C; Jacob O; Reyes E; Novoa C; Orellana S; Orellana N
    Urol Oncol; 2016 Oct; 34(10):430.e17-25. PubMed ID: 27381896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis.
    Callegaro D; Miceli R; Bonvalot S; Ferguson P; Strauss DC; Levy A; Griffin A; Hayes AJ; Stacchiotti S; Pechoux CL; Smith MJ; Fiore M; Dei Tos AP; Smith HG; Mariani L; Wunder JS; Pollock RE; Casali PG; Gronchi A
    Lancet Oncol; 2016 May; 17(5):671-80. PubMed ID: 27068860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.